ThinPrep® Pap Test

A wealth of knowledge in a single vial

The only liquid-based Pap test with FDA approval/clearance for sample collection of Pap, HPV, chlamydia/gonorrhea, and trichomoniasis testing from the same vial.

ThinPrep® Pap test:
FDA Approved
  • ThinPrep® Pap test
  • Aptima® HPV assay
  • Aptima® HPV 16 18/45
    genotype assay
  • cobas® HPV test
  • cobas® AMPLICOR CT/NG test
  • Hybrid Capture® 2 HPV test
FDA Cleared
  • Aptima Combo 2® assay
  • Aptima® Trichomonas
    vaginalis assay
  • ProbeTec® Chlamydia
    trachomatis (CT) test
  • ProbeTec® Neisseria
    gonorrhoeae (GC) test

The ThinPrep® Pap Test collection process provides:

Hologic_Icon_1

Patient Comfort

Out-of-the-vial testing minimizes
the number of samples required
for multiple test results.

Hologic_Icon_2

Clinician Versatility

Multiple FDA-approved ancillary
testing options available from a single vial.

Hologic_Icon_3

Chain-of-Custody Verification

Closed-system lab processing limits opportunities for chain-of-custody errors.

Sample integrity and preservation

Collection device rinsed
in ThinPrep vial.

Full contents of vial preserved
for use in slide presentation.

Raising the bar in Pap testing results

Imaging elevates workflow in your lab and provides greater LSIL and HSIL
categorization versus non-imaged slides.

The College of American Pathologists reported increased HSIL and LSIL categorization rates in labs that used the ThinPrep Pap test in 676 U.S. laboratories.2
HSIL Reporting Rate % (50th pctl) 2
LSIL Reporting Rate % (50th pctl) 2
Slides screened with the ThinPrep® Imaging system showed greater LSIL and HSIL categorization versus non-imaged slides
Independent Studies Show Increased LSIL and HSIL Cytology Categorization vs Manual ThinPrep Pap Test

This chart is a representation of clinical data from multiple published sources. The clinical studies represented within these sources were conducted using different study designs with various assays.

Refer to the ThinPrep Imaging System Instructions for Use for results of FDA approved studies.

UNSAT Rate 5
ASCUS Rate 5

A thorough approach to cervical cancer detection

While introduction of the Pap smear has steadily decreased squamous cell carcinoma, adenocarcinoma remains of great concern. Detecting adenocarcinoma should be an essential part of comprehensive cervical cancer screening.7
Histological Subtypes of Cervical Cancer 7,8
Acog_Logo

Addressing a dangerous threat

The ThinPrep® Pap test is the only Pap test with FDA-approved labeling citing multiple peer-reviewed publications supporting increased glandular disease detection compared to the conventional pap. 9,10,11,12,13,14

Sensitivity for cervical adenocarcinoma8

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?